LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Universal Screening for Chlamydia and Gonorrhea

One in two people diagnosed with an STI will acquire it by age 25.1 CT and NG are commonly asymptomatic. Many patients don’t know they are at risk or that they are infected. CDC guidelines state sexually active women under the age of 25 or women age 25 and older at increased risk should be screened annually, even if they don’t have symptoms.1,2

A universal screening CT/NG strategy would target women within the high-risk age group covered by guidelines from USPSTF and CDC (women 15-24 years old) without regard to sexual activity they report.2,3 Women 15-24 years old could be tested, unless their record is flagged when they check in that they have had a negative test within the past year, or they did not want to be tested. As a health care provider you would say to patients, “We are going to test you today, unless you opt out.”

Universal Screening may help to:4

  • Decrease STI prevalence
  • Decrease infertility due to undiagnosed infections
  • Reduce health care costs

LabCorp offers CT and NG test options from a number of collection devices, giving you and your patient’s convenient options.

LabCorp offers a wide range of CT and NG testing options.

For more information, please download the following brochures:

Universal Screening for Chlamydia and Gonorrhea   Chlamydia and Gonorrhea   Chlamydia, Gonorrhea, and Trichomonas

Reference

  1. Centers for Disease Control and Prevention. STDs in Adolescents and Young Adults. https://www.cdc.gov/std/stats16/adolescents.htm. Accessed April 19, 2018
  2. CDC. STD & HIV Screening Recommendations. https://www.cdc.gov/std/prevention/screeningreccs.htm. Updated April 27, 2017. Accessed April 13, 2018
  3. USPSTF. Final recommendation Statement: Chlamydia and Gonorrhea Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/Recommendati.... Published December 2016. Accessed April 13, 2018
  4. Owusu-Edusei K, Hoover KW, Gift TL. Cost-effectiveness of opt-out chlamydia testing for high-risk young women in the U.S. Am J Prev Med. 2016;51(2):216-24. doi: 10.1016/j. amepre.2016.01.007